Accessibility Menu

Purple Biotech(NASDAQ) KTOV

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-95%
1 Month-18%
N/A
Purple Biotech last closing stock price
MetricPriceDate
Last closeUSD 1.432026-07-24
Purple Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.72%USD 1.472026-07-17
1 month-18.29%USD 1.752026-06-24
3 month-68.5%USD 4.542026-04-24
Year to date-78.25%USD 6.582025-12-31
1 year-94.54%USD 26.202025-07-24
3 year-99.4%USD 240.002023-07-25
5 year-99.86%USD 990.002021-07-23
Since inception-99.98%USD 5,980.002015-11-23

Purple Biotech Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.30

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

KTOV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Purple Biotech

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Industry

Pharmaceuticals

Sector

Health Care

Employees

10

CEO

Gil Efron, MBA, CPA

Website

www.purple-biotech.com

KTOV Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

N/A

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$1.00M

Operating Income

$0.00

EBITDA

$178.00K

Operating Cash Flow

-$5.58M

Capital Expenditure

$0.00

Free Cash Flow

-$5.58M

Cash & ST Invst.

$4.39M

Total Debt

$0.00

Purple Biotech Performance Analysis

Purple Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Purple Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -233.5613.0%
20232023-12-31USD -161.08-31.0%
20242024-12-31USD -28.13-82.5%
20252025-12-31USD -55.4096.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$0.06

+1.4%

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.38

N/A

Employees

10

N/A

Net Income

-$0.09

+0.2%

EBITDA

-$2.18

+1.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.75

-2.7%

Total Debt

$0.18

+1.3%

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.18

+1.3%

Return on Assets

-104.76%

+10.1%

Return on Invested Capital

-85.29%

+2.3%

Free Cash Flow

-$3.07

+1.0%

Operating Cash Flow

-$3.07

+1.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,396.49-0.00%
^DJIDJI
$52,083.00+0.00%
^IXICNASDAQ
$24,847.16-0.01%
BTCBitcoin
$64,796.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About KTOV

What is the current price of Purple Biotech?

Purple Biotech is trading at N/A per share.

What is the 52-week range for Purple Biotech?

Over the past 52 weeks, Purple Biotech has traded between N/A and N/A.

How much debt does Purple Biotech have?

As of the most recent reporting period, Purple Biotech reported total debt of $184.00K.

How much cash does Purple Biotech have on hand?

Purple Biotech reported $5.57M in cash and cash equivalents in its most recent financial results.

What is Purple Biotech’s dividend yield?

Purple Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services